BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2695534)

  • 1. [Immunotherapy and cancer: the role of monoclonal antibodies].
    Dumontet C
    J Chir (Paris); 1989 Dec; 126(12):682-6. PubMed ID: 2695534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and immunologic therapy of ovarian cancer.
    Bookman MA; Berek JS
    Hematol Oncol Clin North Am; 1992 Aug; 6(4):941-65. PubMed ID: 1500395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current possibilities in immunotherapy of cancer].
    von Fliedner V
    Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors.
    Douillard JY; Lehur PA; Vignoud J; Blottière H; Maurel C; Thedrez P; Kremer M; Le Mevel B
    Hybridoma; 1986 Jul; 5 Suppl 1():S139-49. PubMed ID: 3527945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS; Quezada SA; Korman AJ; Allison JP
    Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress review: intrathecal and intratumoral injection of radiolabelled monoclonal antibodies (MoAbs) for the treatment of central nervous system (CNS) malignancies.
    Hopkins K; Kemshead JT
    J Drug Target; 1993; 1(3):175-83. PubMed ID: 8069558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor immunotherapy].
    Błoński JZ; Warzocha K
    Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 1998; 70(5):32-7. PubMed ID: 9644739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P
    Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.